Company intelligence / Profile preview

Melanovus Oncology

Jensen Beach, Florida, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Seven pre-clinical compounds (including Nanolipolee-007) demonstrated efficacy in vitro and early in vivo models, with plans for IND-enabling work prior to acquisition by Cipher Pharmaceuticals. No clinical trial results; all work was preclinical.

Therapeutic areas: Oncology
Modalities: Small moleculeNanoparticle
Industry: Biotech

Partnerships

Penn State Research Foundation (licensing of core technology)

Beyond the preview

Go deeper on Melanovus Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Melanovus Oncology.

Explore the full profile